Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01610206 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
A Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Linda R Duska.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 8
- Study locations
NCT01610206 is a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Linda R Duska. The registered enrollment target is 148 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (80% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT01610206, a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Linda R Duska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 8
- Study locations
Study Summary
Ovarian cancer is the leading cause of gynecologic cancer deaths, and the fifth most common cause of cancer deaths in women. While approximately 75% of patients with epithelial ovarian cancer will respond to first-line chemotherapy with platinum and paclitaxel, most patients with advanced stage epithelial ovarian cancer will experience disease recurrence. Pazopanib is a novel agent has recently been approved for the treatment of subjects with advanced renal cell carcinoma (RCC), and preclinical studies suggest it may be effective in other cancers such as ovarian cancer. Therefore, the purpose of this study is to test the efficacy and safety of a novel agent, pazopanib, as an adjunct to a standard treatment, gemcitabine, for recurrent or persistent ovarian cancer. This is an open label study in which subjects will be randomized 1:1 to receive 4 cycles of either gemcitabine, or gemcitabine with pazopanib. Gemcitabine will be administered as an IV infusion weekly on days 1 and 8 of a 21 day cycle. Subjects randomized to receive pazopanib will take 800 mg daily during the 21 day cycle. All subjects will be monitored for toxicity and other indicators of safety (labs, physical exams, vitals) at intervals throughout the treatment cycles. Subjects will be followed for up to 5 years following the conclusion of treatment to evaluate efficacy. The primary endpoints of the study are progression free survival and overall survival, which will be assessed at three years.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG pazopanib
Study Locations (8)
Virginia
- University of Virginia - Charlottesville
- Virginia Commonwealth University - Richmond
Maine
- Maine Medical Center (MMP Women's Health) - Scarborough
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
North Carolina
- Duke University - Durham
Oklahoma
- Stephenson Cancer Center University of Oklahoma Health Sciences Center - Oklahoma City
Texas
- MD Anderson - Houston
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2012-09 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01610206
The ClinicalTrials.gov registry entry for NCT01610206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Linda R Duska, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT01610206 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Virginia, Maine, Maryland.
Frequently Asked Questions
What is clinical trial NCT01610206 about?
NCT01610206 is a clinical study titled "A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer". Ovarian cancer is the leading cause of gynecologic cancer deaths, and the fifth most common cause of cancer deaths in women. While approximately 75% of patients with epithelial ovarian cancer will respond to first-line chemotherapy with platinum and paclitaxel, most patients with advanced stage epit...
What is the current status of trial NCT01610206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2012-09. Estimated completion is 2020-12-31.
What conditions does trial NCT01610206 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT01610206?
The interventions under investigation include: Gemcitabine (DRUG), pazopanib (DRUG).
Who is sponsoring clinical trial NCT01610206?
This trial is sponsored by Linda R Duska, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01610206 being conducted?
This trial has 8 study locations across Maine, Maryland, North Carolina, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.